PolyPeptide H1 EBITDA Rises

PolyPeptide reported a widened first-half net loss of €26.5 million, yet concurrently saw robust revenue growth of 23.7% to €167.1 million, primarily driven by metabolic therapeutics, and a 54.6% increase in EBITDA to €4.4 million. Reflecting this operational performance, the company revised its full-year 2025 revenue growth guidance towards the upper end of the 13-20% constant currency range and confirmed its mid-term outlook, projecting a high single-digit/low double-digit EBITDA margin for 2025.

Analysis

PolyPeptide's first-half results present a mixed financial picture, characterized by strong top-line momentum offset by deteriorating bottom-line profitability. The company reported a 23.7% year-over-year increase in revenue to €167.1 million, driven primarily by its metabolic therapeutics segment, and a significant 54.6% surge in EBITDA to €4.4 million. Despite this operational growth, the net loss widened considerably to €26.5 million from €11.4 million in the prior year, with loss per share increasing to €0.80 from €0.35. Management's confidence in its growth trajectory is evident in its revised full-year 2025 guidance, which now anticipates revenue growth toward the upper end of the 13-20% constant currency range. This positive outlook is further supported by a confirmed mid-term outlook and a projected 2025 EBITDA margin in the high single-digit to low double-digit range, signaling a potential future path to improved profitability.

Key Decisions for Investors

• Investors should weigh the company's robust revenue expansion and positive 2025 guidance against the widening net loss to assess if the growth narrative justifies the current lack of profitability.
• The upward revision to revenue guidance and the projected improvement in EBITDA margin for 2025 are key bullish signals, suggesting potential upside for investors confident in management's execution capabilities.
• It is critical to monitor future earnings for tangible progress towards the guided high single-digit/low double-digit EBITDA margin, as this will be a key determinant in validating the company's long-term value proposition.